Pfizer gets outperform from Bear Stearns

Pfizer Inc. was rated at outperform with a $30 price target by Bear Stearns analyst John Boris, who is expecting the company to post third-quarter adjusted earnings per share of $0.45 (-9%), in line with consensus. Lipitor sales are expected to come in at $3.01billion (+4%) and Norvasc sales at $1.12 billion, (-1%), Lyrica sales at $290 million, Celebrex at $498 million (+12%), Viagra at $399 million (+3%) and Zyrtec at $365 million (+8%). Shares of the New York, N.Y., pharmaceutical company were up 38 cents, or 1.37%, at $28.10. (NYSE: PFE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.